In the VALOR study, a randomized controlled trial evaluating the antisense oligonucleotide Tofersen in patients with SOD1-mutated ALS, a significant reduction in plasma NfL levels was observed following treatment, although this was not paralleled by a clear clinical benefit [5]. Here, SOD1 is linked to amyotrophic lateral sclerosis.